The Medicines Adaptive Pathways to Patients (MAPPs) and its importance in oncology

Bettina Ryll, MD, PhD of Melanoma Patient Network Europe talks about the role of drug development and clinical trials for oncology. Dr Ryll believes that the Medicines Adaptive Pathways to Patients (MAPPs) of the European Medicines Agency (EMA) is an important tool in oncology to combine early access to innovation with systematic learning. Recorded at the 2016 annual meeting of the European Society of Medical Oncology (ESMO), held in Copenhagen, Denmark.
Share this video